Table 1.
Clinical and demographic characteristics of individuals with schizophrenia (N=60)
| Mean or N (%) | S.D. | |
|---|---|---|
| Age | 44.78 (9.877) | |
| Gender, male | 31 (51.7%) | |
| Education | 11.18 | 2.891 |
| Age of onset | 25.4 | 8.166 |
| Illness duration (years) | 19.38 | 8.019 |
| PANSS Positive | 16.55 | 2.594 |
| PANSS Negative | 17.48 | 1.855 |
| PANSS General | 35.95 | 4.276 |
| PANSS Total | 69.98 | 7.019 |
| TALD Objective Positive | 13.85 | 9.231 |
| TALD Objective Negative | 3.00 | 2.731 |
| TALD Subjective Positive | 1.98 | 1.996 |
| TALD Subjective Negative | 9.70 | 5.036 |
| TALD Total | 28.53 | 12.506 |
| First generation antipsychotics | 16 (26.67%) | |
| Second generation antipsychotics | 52 (86.67%) | |
| Olanzapine | 9 (15.0%) | |
| Aripiprazole | 9 (15.0%) | |
| Risperidone | 9 (15.0%) | |
| Quetiapine | 8 (13.3%) | |
| Paliperidone | 7 (11.7%) | |
| Clozapine | 7 (11.7%) | |
| Amisulpride | 5 (8.3%) | |
| Zotepine | 2 (3.3%) | |
| DM | 6 (10.0%) | |
| Hypertension | 12 (20.0%) | |
| BMI | 25.97 | 4.809 |
| CRP | 0.405 | 0.879 |
| CRP, mg/dL | 0.14 [0.065, 0.365] | Median [Q1, Q3] |
| CRP level after log-transformation | −1.86±1.32 | Mean ± SD |
Abbreviations: PANSS, Positive and Negative Syndrome Scale; TALD, Thought and Language Disorder Scale; DM, diabetes mellitus; BMI, body mass index; CRP, C-reactive protein.